Cambridge Epigenetix Ltd has raised $21 million in a Series B equity financing for the further development of its epigenetic tools for analysing the DNA methylome. Prominent financers from California, US provided the bulk of the funding. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
